265 related articles for article (PubMed ID: 21216196)
1. The fitness of antimony-resistant Leishmania parasites: lessons from the field.
Ait-Oudhia K; Gazanion E; Oury B; Vergnes B; Sereno D
Trends Parasitol; 2011 Apr; 27(4):141-2. PubMed ID: 21216196
[No Abstract] [Full Text] [Related]
2. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.
Goyeneche-Patino DA; Valderrama L; Walker J; Saravia NG
Antimicrob Agents Chemother; 2008 Dec; 52(12):4503-6. PubMed ID: 18824610
[TBL] [Abstract][Full Text] [Related]
3. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
4. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of antimony resistance in Leishmania.
Ashutosh ; Sundar S; Goyal N
J Med Microbiol; 2007 Feb; 56(Pt 2):143-53. PubMed ID: 17244793
[TBL] [Abstract][Full Text] [Related]
6. Leishmania antimony resistance: what we know what we can learn from the field.
Aït-Oudhia K; Gazanion E; Vergnes B; Oury B; Sereno D
Parasitol Res; 2011 Nov; 109(5):1225-32. PubMed ID: 21800124
[TBL] [Abstract][Full Text] [Related]
7. Leishmania spp.: proficiency of drug-resistant parasites.
Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
[TBL] [Abstract][Full Text] [Related]
8. Multilocus genotyping reveals a polyphyletic pattern among naturally antimony-resistant Leishmania braziliensis isolates from Peru.
Adaui V; Maes I; Huyse T; Van den Broeck F; Talledo M; Kuhls K; De Doncker S; Maes L; Llanos-Cuentas A; Schönian G; Arevalo J; Dujardin JC
Infect Genet Evol; 2011 Dec; 11(8):1873-80. PubMed ID: 21871584
[TBL] [Abstract][Full Text] [Related]
9. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
Rezzano S; Armas JA; Moreno G; Scorza JV
Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
[No Abstract] [Full Text] [Related]
10. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Kothari H; Kumar P; Sundar S; Singh N
Parasitol Int; 2007 Mar; 56(1):77-80. PubMed ID: 17169604
[TBL] [Abstract][Full Text] [Related]
11. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania.
Marquis N; Gourbal B; Rosen BP; Mukhopadhyay R; Ouellette M
Mol Microbiol; 2005 Sep; 57(6):1690-9. PubMed ID: 16135234
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of nicotinamide/antileishmanial drug combinations.
Gazanion E; Vergnes B; Seveno M; Garcia D; Oury B; Ait-Oudhia K; Ouaissi A; Sereno D
Parasitol Int; 2011 Jan; 60(1):19-24. PubMed ID: 20884376
[TBL] [Abstract][Full Text] [Related]
13. The LABCG2 Transporter from the Protozoan Parasite Leishmania Is Involved in Antimony Resistance.
Perea A; Manzano JI; Castanys S; Gamarro F
Antimicrob Agents Chemother; 2016 Jun; 60(6):3489-96. PubMed ID: 27021316
[TBL] [Abstract][Full Text] [Related]
14. Characterization of natural antimony resistance in Leishmania donovani isolates.
Mittal MK; Rai S; Ashutosh ; Ravinder ; Gupta S; Sundar S; Goyal N
Am J Trop Med Hyg; 2007 Apr; 76(4):681-8. PubMed ID: 17426170
[TBL] [Abstract][Full Text] [Related]
15. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
[TBL] [Abstract][Full Text] [Related]
16. Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients.
Inocêncio da Luz R; Romero GA; Dorval ME; Cruz I; Cañavate C; Dujardin JC; Van Assche T; Cos P; Maes L
J Antimicrob Chemother; 2011 Mar; 66(3):677-9. PubMed ID: 21393233
[No Abstract] [Full Text] [Related]
17. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
Croft SL; Coombs GH
Trends Parasitol; 2003 Nov; 19(11):502-8. PubMed ID: 14580961
[No Abstract] [Full Text] [Related]
18. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
19. [Search for and development of antileishmaniasis preparations (a review of the literature)].
Chistiakov DA; Drabkina AA; Rusak LV
Med Parazitol (Mosk); 1982; 51(4):57-63. PubMed ID: 6752683
[No Abstract] [Full Text] [Related]
20. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
